

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/722,104 Confirmation No.: 6396  
Applicants : Daniel P. Becker  
Filed : November 25, 2003  
Title : HETEROARYLSULFONYLMETHYL HYDROXAMIC ACIDS AND  
THEIR USE AS PROTEASE INHIBITORS  
TC/AU : 1625  
Examiner : Davis, Zinna Northington  
Docket No. : PC27788  
Customer No. : 25533

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**REMARKS**

Dear Sir:

Applicants are filing two terminal disclaimers herewith. The first disclaims the term beyond U.S. 6,890,937. The second disclaims the term beyond U.S. 6,541,489. As Applicants and the Examiner discussed in a telephone conversation of July 6, 2007, the only remaining issues in this case are nonstatutory double patenting rejections. Accordingly, Applicants respectfully request withdrawal of the nonstatutory double patenting rejection in view of the terminal disclaimers. Applicants respectfully request allowance of the instant application in view of the submission of these terminal disclaimers.

The Terminal Disclaimers are accompanied by a Fee Transmittal Sheet authorizing payment of the appropriate fees under 37 C.F.R. 1.20(d).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States

Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Respectfully submitted,

JULY 6, 2007  
Date

John H. Engelman  
John H. Engelman  
Reg. No. 28,075  
Pfizer Inc.  
7000 Portage Road  
Kalamazoo, MI 49001  
Tel. (269) 833-2532  
Fax (269) 833-8897